Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SYNTEX FEMSTAT (BUTOCONAZOLE NITRATE) REDUCED THERAPY TIME

Executive Summary

SYNTEX FEMSTAT (BUTOCONAZOLE NITRATE) REDUCED THERAPY TIME is being emphasized by the firm in an announcement of the product's approval. Femstat "is the first three-day cream for the treatment of vaginal yeast infections in non-pregnant patients. In pregnant patients, six-day treatment is recommended . . . In contrast, all other currently available cream therapies must be used for at least seven days," Syntex said in a recent press release. FDA approved Femstat (butoconazole 2% cream) as a 1C antifungal agent, a classification indicating that the drug is a new chemical entity representing little therapeutic gain. A suppository form containing 100 mg butoconazole was also cleared by the agency. The firm said that Femstat is highly effective in treating candidiasis, a common form of vaginitis that can cause itching, unusual discharge and pain during intercourse. Syntex stated that, "unlike suppositories and inserts, ]Femstat[ cream can be applied externally to treat symptoms such as itching and soreness. Femstat's low rate of absorption means it stays mainly on surface tissues at the application site, where most of the infecting fungi are." Syntex said it will begin marketing the new product during the first quarter, and that physicians can start prescribing Femstat in mid-February.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel